Lifecore Biomedical Inc. (LFCR): Price-to-Revenue Ratio

Symbol and logo of brand Lifecore (LFCR)

The price-to-sales ratio of Lifecore Biomedical (LFCR) demonstrates growth potential amid a shortage of sterile injectables and an expanding customer base. Lifecore Biomedical is scaling the production of biomaterials and hyaluronate while simultaneously reducing its environmental footprint and harmful emissions. As part of its ESG strategy, the business strictly adheres to bioethics, and the 1.30 metric serves as the target level for assessing current market value.

lifecore.com (LFCR): P/S Multiple from 04/28/2023 to 08/31/2026

Analytical breakdowns for Lifecore Biomedical (LFCR)

- price and consensus price forecast:
Market Chart lifecore.com|LFCR - Price Target Chart
- stock exchange capitalization data:
Market Value Lifecore|LFCR - Enterprise Value
- issuer book value statistics:
Net Assets per Share Lifecore Biomedical|LFCR - Book Capitalization|Market Capitalization to Net Assets lifecore.com|LFCR - Company Total Assets
- debt obligations and liquidity statistics:
Debt to Capital Lifecore Biomedical|LFCR - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio lifecore.com|LFCR - Company Debts|Debts to Book Value Lifecore|LFCR - Company Long-Term Debt|Company Short-Term Loans and Borrowings Lifecore Biomedical|Immediate Liquidity lifecore.com
- net income and valuation ratios data:
LFCR - Net Income|Expected Net Income Lifecore Biomedical|LFCR - P/E Multiple|Future Price to Earnings lifecore.com|LFCR - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Lifecore|LFCR - Profit before payment of interest, taxes and amortization|Net earnings per one share for the last twelve months Lifecore Biomedical|LFCR - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months lifecore.com|LFCR - Earnings growth in current year|Expected net earnings per share growth next year Lifecore Biomedical
- issuer revenue and sales details:
LFCR - Revenue and Sales Volume|Company Revenue Forecast lifecore.com|LFCR - P/S Multiple|Market Cap to Expected Sales Ratio Lifecore
Fundamental company analysis:LFCR - Lifecore Biomedical Inc.
Mass-produced product of Lifecore Biomedical, Inc.

To minimize fundamental risks, investors should evaluate the market value of a business relative to its operating income. This price-to-sales ratio is calculated as the ratio of market capitalization to annual revenue, demonstrating a premium or discount relative to actual sales. For Lifecore Biomedical (LFCR) and its protected cGMP contracts, this chart helps determine whether the market is fairly pricing the high barriers to entry for competitors in the sterile injectables niche.

Competitors of Lifecore Biomedical

Price-to-Revenue Coefficient iqvia.com|Price-to-Revenue Ratio Labcorp LH|Medpace Holdings - Price-to-Revenue Ratio|ICON Corp - P/S Multiple|Price-to-Revenue Coefficient Charles River Corp CRL|EVO: P/S Multiple|Price-to-Sales Ratio FTRE (fortrea.com)|OABI (OmniAb) - P/S Multiple|Price to Sales Inotiv Inc NOTV|P/S Multiple CDMO|Market Cap to Revenue Catalent, Inc CTLT|Price-to-Revenue Ratio Scorpius Holdings, Inc. SCPX